- Home
- ERIC vs BIIB Comparison
ERIC vs BIIB Comparison
Compare ERIC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERIC
- BIIB
- Stock Information
- Founded
- ERIC 1876
- BIIB 1978
- Country
- ERIC Sweden
- BIIB United States
- Employees
- ERIC N/A
- BIIB N/A
- Industry
- ERIC Radio And Television Broadcasting And Communications Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ERIC Technology
- BIIB Health Care
- Exchange
- ERIC Nasdaq
- BIIB Nasdaq
- Market Cap
- ERIC 31.7B
- BIIB 18.7B
- IPO Year
- ERIC N/A
- BIIB 1991
- Fundamental
- Price
- ERIC $10.06
- BIIB $151.35
- Analyst Decision
- ERIC Hold
- BIIB Buy
- Analyst Count
- ERIC 1
- BIIB 25
- Target Price
- ERIC $9.80
- BIIB $183.05
- AVG Volume (30 Days)
- ERIC 23.0M
- BIIB 1.6M
- Earning Date
- ERIC 10-14-2025
- BIIB 10-30-2025
- Dividend Yield
- ERIC 1.92%
- BIIB N/A
- EPS Growth
- ERIC N/A
- BIIB N/A
- EPS
- ERIC 0.78
- BIIB 10.97
- Revenue
- ERIC $25,502,929,121.00
- BIIB $10,065,900,000.00
- Revenue This Year
- ERIC N/A
- BIIB $2.03
- Revenue Next Year
- ERIC $0.71
- BIIB N/A
- P/E Ratio
- ERIC $13.04
- BIIB $13.64
- Revenue Growth
- ERIC N/A
- BIIB 4.77
- 52 Week Low
- ERIC $6.64
- BIIB $110.04
- 52 Week High
- ERIC $10.35
- BIIB $185.00
- Technical
- Relative Strength Index (RSI)
- ERIC 73.77
- BIIB 60.25
- Support Level
- ERIC $9.96
- BIIB $138.00
- Resistance Level
- ERIC $10.35
- BIIB $154.44
- Average True Range (ATR)
- ERIC 0.23
- BIIB 4.35
- MACD
- ERIC 0.05
- BIIB 0.03
- Stochastic Oscillator
- ERIC 72.09
- BIIB 81.20
About ERIC Ericsson
Ericsson provides telecom equipment and services that are primarily used to build and operate mobile networks. The firm divides its business into three segments: networks, cloud and software services, and enterprise. Wireless carriers have traditionally been the firm's primary customers, but it is pushing to cater more to enterprises as well, as both try to take advantage of 5G capabilities and utilize "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.